Kishimoto T - Search Results

1

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Nishimoto N, et al. Among authors: kishimoto t. Arthritis Rheum. 2004 Jun;50(6):1761-9. doi: 10.1002/art.20303. Arthritis Rheum. 2004. PMID: 15188351 Free article. Clinical Trial.

2

The paradigm of IL-6: from basic science to medicine.

Naka T, Nishimoto N, Kishimoto T. Naka T, et al. Among authors: kishimoto t. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S233-42. doi: 10.1186/ar565. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110143 Free PMC article. Review.

3

Synergistic effect on the attenuation of collagen induced arthritis in tumor necrosis factor receptor I (TNFRI) and interleukin 6 double knockout mice.

Yamaguchi N, Ohshima S, Umeshita-Sasai M, Nishioka K, Kobayashi H, Mima T, Kishimoto T, Saeki Y. Yamaguchi N, et al. Among authors: kishimoto t. J Rheumatol. 2003 Jan;30(1):22-7. J Rheumatol. 2003. PMID: 12508385

4

Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice.

Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y. Katsume A, et al. Among authors: kishimoto t. Cytokine. 2002 Dec 21;20(6):304-11. doi: 10.1006/cyto.2002.2012. Cytokine. 2002. PMID: 12633573

5

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Nakahara H, et al. Among authors: kishimoto t. Arthritis Rheum. 2003 Jun;48(6):1521-9. doi: 10.1002/art.11143. Arthritis Rheum. 2003. PMID: 12794819 Free article.

6

Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.

Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Takagi N, Kishimoto T. Nishimoto N, et al. Among authors: kishimoto t. J Rheumatol. 2003 Jul;30(7):1426-35. J Rheumatol. 2003. PMID: 12858437 Clinical Trial.

7

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. Ito H, et al. Among authors: kishimoto t. Gastroenterology. 2004 Apr;126(4):989-96; discussion 947. doi: 10.1053/j.gastro.2004.01.012. Gastroenterology. 2004. PMID: 15057738 Clinical Trial.

8

Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis.

Mihara M, Shiina M, Nishimoto N, Yoshizaki K, Kishimoto T, Akamatsu K. Mihara M, et al. Among authors: kishimoto t. J Rheumatol. 2004 Jun;31(6):1132-8. J Rheumatol. 2004. PMID: 15170926

9

Inhibition of IL-6 for the treatment of inflammatory diseases.

Nishimoto N, Kishimoto T. Nishimoto N, et al. Among authors: kishimoto t. Curr Opin Pharmacol. 2004 Aug;4(4):386-91. doi: 10.1016/j.coph.2004.03.005. Curr Opin Pharmacol. 2004. PMID: 15251133 Review.

10

Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes.

Fujio Y, Matsuda T, Oshima Y, Maeda M, Mohri T, Ito T, Takatani T, Hirata M, Nakaoka Y, Kimura R, Kishimoto T, Azuma J. Fujio Y, et al. Among authors: kishimoto t. FEBS Lett. 2004 Aug 27;573(1-3):202-6. doi: 10.1016/j.febslet.2004.07.082. FEBS Lett. 2004. PMID: 15327998 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,045 results

Search Page

Filters